Literature DB >> 20058239

The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.

Karen M Hill1, Sara Kalifa, Jharna R Das, Tahira Bhatti, Martha Gay, Danielle Williams, Latonia Taliferro-Smith, Angelo M De Marzo.   

Abstract

BACKGROUND: Class IA PI 3-kinases produce phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 is bound by AKT which facilities its activation by PDK1. Activated AKT promotes cell survival and stimulates cell proliferation. Class IA PI 3-kinases are heterodimers consisting of a regulatory subunit p85 and a catalytic subunit p110. The p110alpha isoform has been shown to be mutated in a number of tumor types. A number of recent studies suggest that the p110beta isoform may be functionally relevant in prostate cancer. In this study we extend this work to include the examination of the expression and functional properties of p110alpha and p110beta in three different prostate cancer cell lines, DU145, LNCaP, PC3, as well as the non-tumorigenic but immortalized RWPE1 prostate epithelial cell line.
METHODS: Western blot analysis was used to measure protein expression and quantitative real-time PCR was used to measure mRNA levels. After targeted knockdown using isoform-specific siRNAs to reduce PI 3-kinase p110alpha or p110beta isoform expression, we measured downstream signally events such as phosphorylation of AKT, ERK 1/2, PDK, and FOXO, as well as biological consequences such as changes in apoptosis, and alterations in cell cycle progression.
RESULTS: In all three prostate cancer cell lines examined, targeted knockdown of p110beta, and not p110alpha, resulted in significantly reduced AKT, PDK, and FOXO phosphorylation. While knockdown of either p110 isoform resulted in an increase in apoptosis and a cell cycle arrest in G1 in the remaining non-apoptotic cells, these effects were much more pronounced with knockdown of p110beta.
CONCLUSIONS: Our results support the concept that p110beta appears to be the predominant functional class I PI 3-kinase isoform in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20058239     DOI: 10.1002/pros.21108

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  26 in total

1.  A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.

Authors:  Hashem A Dbouk; Huan Pang; Andras Fiser; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

Review 2.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

Review 3.  Targeting the PI3K pathway for cancer therapy.

Authors:  Navid Sadeghi; David E Gerber
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

4.  Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.

Authors:  Hong Lin; Mark J Schulz; Ren Xie; Jin Zeng; Juan I Luengo; Michael D Squire; Rosanna Tedesco; Junya Qu; Karl Erhard; James F Mack; Kaushik Raha; Ramona Plant; Cynthia M Rominger; Jennifer L Ariazi; Christian S Sherk; Michael D Schaber; Jeanelle McSurdy-Freed; Michael D Spengler; Charles B Davis; Mary Ann Hardwicke; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2012-05-29       Impact factor: 4.345

5.  [3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors.

Authors:  Hongyi Yu; Michael L Moore; Karl Erhard; Mary Ann Hardwicke; Hong Lin; Juan I Luengo; Jeanelle McSurdy-Freed; Ramona Plant; Junya Qu; Kaushik Raha; Cynthia M Rominger; Michael D Schaber; Michael D Spengler; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2013-01-10       Impact factor: 4.345

Review 6.  PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

Authors:  Benyi Li; Aijing Sun; Wencong Jiang; J Brantley Thrasher; Paul Terranova
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 7.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

8.  A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability.

Authors:  Pierre-Olivier Estève; Yanqi Chang; Mala Samaranayake; Anup K Upadhyay; John R Horton; George R Feehery; Xiaodong Cheng; Sriharsa Pradhan
Journal:  Nat Struct Mol Biol       Date:  2010-12-12       Impact factor: 15.369

Review 9.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

10.  Induced PDK1 kinase activity suppresses apoptosis in intestinal epithelial cells by activating Akt signaling following polyamine depletion.

Authors:  Kaspar M Keledjian; Bernard S Marasa; Jian-Ying Wang; Jaladanki N Rao
Journal:  Int J Clin Exp Med       Date:  2012-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.